Compare Davita Inc (DVA) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Wolfspeed Inc — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while Wolfspeed Inc trades at $36.25 (market cap $1.78B). The key difference: Davita Inc is far larger — about 8.4× Wolfspeed Inc's market cap, and Davita Inc is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| DVA | WOLF | |
|---|---|---|
Market Cap | $14.92B | $1.78B |
Sector | Health | Technology |
52-Week High | $235.71 | $73.68 |
52-Week Low | $103.87 | $1.19 |
Enterprise Value | $27.47B | $2.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Wolfspeed (WOLF) trades at $33.65, down 4.65% today amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with recent beats but a significant Q4 2025 miss. Recent developments include a patent lawsuit against Navitas Semiconductor and strategic partnerships with GE Aerospace, positioning the company in high-growth AI and defense markets despite current financial challenges.
The outlook remains cautious with analyst consensus leaning neutral (47.37% Hold). While strategic pivots to data centers and defense offer growth potential, negative margins and bearish technicals present near-term risks. Investors should monitor earnings improvement and market share gains in silicon carbide technology for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
